Christopher Martell - Jul 26, 2021 Form 3 Insider Report for Candel Therapeutics, Inc. (CADL)

Role
Director
Signature
/s/ Christopher Martell
Stock symbol
CADL
Transactions as of
Jul 26, 2021
Transactions value $
$0
Form type
3
Date filed
7/26/2021, 09:20 PM
Next filing
Aug 2, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CADL Stock Option (Right to Buy) Jul 26, 2021 Common Stock 16.3K $1.55 Direct F1
holding CADL Stock Option (Right to Buy) Jul 26, 2021 Common Stock 16.3K $6.64 Direct F1
holding CADL Series B Preferred Stock Jul 26, 2021 Common Stock 284K $6.81 By GTAM1 2012 ADV LLC F2, F3
holding CADL Warrants to purchase Common Stock Jul 26, 2021 Common Stock 284K $6.81 By GTAM1 2012 Trust F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option is fully vested and exercisable as of the date hereof.
F2 The Series B Preferred Stock has no expiration date.
F3 Shares held by GTAM1 2012 ADV LLC, for which the Reporting Person serves as manager. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.
F4 Warrants held by GTAM1 2012 Trust, for which the Reporting Person serves as trustee but is not a beneficiary. The Reporting Person disclaims beneficial ownership of these warrants except to the extent of his pecuniary interest therein, if any.